Rwanda Social Security Board v. L.E.A.F. Pharmaceuticals, LLC

Court of Chancery of Delaware·Decided December 8, 2023·No. C.A. No. 2022-0987-BWD·Published

Opinion

COURT OF CHANCERY

OF THE

STATE OF DELAWARE

BONNIE W. DAVID COURT OF CHANCERY COURTHOUSE MAGISTRATE IN CHANCERY 34 THE CIRCLE GEORGETOWN, DE 19947

Final Report: December 8, 2023 Date Submitted: November 17, 2023

Philip Trainer, Jr., Esquire Samuel T. Hirzel, II, Esquire Randall J. Teti, Esquire Brendan Patrick McDonnell, Esquire Ashby & Geddes Heyman Enerio Gattuso & Hirzel 500 Delaware Avenue, 8th Floor LLP Wilmington, Delaware 19801 300 Delaware Avenue, Suite 200 Wilmington, Delaware 19801

RE: Rwanda Social Security Board v. L.E.A.F. Pharmaceuticals, LLC, et al., C.A. No. 2022-0987-BWD

Dear Counsel:

In this action, the plaintiff, Rwanda Social Security Board (“RSSB”), brings claims for fraud, negligent misrepresentation, equitable fraud, unjust enrichment, and breach of contract against defendants L.E.A.F. Pharmaceuticals LLC, L.E.A.F.

Holdings Group LLC, and Clet Niyikiza (collectively, “Defendants”) arising from a series of transactions through which RSSB acquired units of L.E.A.F.

Pharmaceuticals LLC. In response to RSSB’s complaint, Defendants filed an answer and counterclaims, alleging that by filing this lawsuit, RSSB committed abuse of process and tortious interference with prospective contractual relations.

RSSB has moved to dismiss Defendants’ counterclaims for failure to state a claim.

In this final report, I recommend that both counterclaims be dismissed.

C.A. No. 2022-0987-BWD December 8, 2023 Page 2 of 15

I. BACKGROUND The following facts are taken from Defendants’ Answer With Affirmative Defenses and Counterclaims (the “Counterclaims”) and the documents incorporated by reference therein, affording Defendants the benefit of all reasonable inferences.

A. The Complaint RSSB is a Rwandan governmental entity that manages the Republic of

Rwanda’s pension, social security, health insurance, savings, disability, and maternity benefits. Verified Compl. [hereinafter, “Compl.”] ¶ 1, Dkt. 1; Defs.’ Ans. With Affirmative Defenses and Countercls. [hereinafter, “Countercls.”] ¶ 1, Dkt. 6.

On October 31, 2022, RSSB initiated this action through the filing of a Verified Complaint (the “Complaint”). The Complaint names as defendants L.E.A.F. Pharmaceuticals LLC (“LEAF”), L.E.A.F. Holdings Group LLC (“Holdings”), and Clet Niyikiza. Compl. ¶¶ 1-4. LEAF is a Delaware limited liability company that develops, manufactures, and commercializes drug therapies. Id. ¶ 2. Holdings, also a Delaware limited liability company, is a founding member of LEAF. Id. ¶ 3. Clet Niyikiza is the founder, President, CEO, and Manager of LEAF. Id. ¶ 4. He is also the founder, owner, and Manager of Holdings. Id.

The Complaint alleges that in March 2017, RSSB and LEAF entered into a Unit Purchase Agreement, pursuant to which RSSB agreed to purchase 429 units of

C.A. No. 2022-0987-BWD December 8, 2023 Page 3 of 15

LEAF for $40 million to be paid in six bi-annual installments from 2017 to 2019, including an upfront payment of $5 million made in February 2017. Id. ¶¶ 9-10. Thereafter, RSSB invested another $5 million in December 2017 and $7.5 million in each of December 2018, March 2019, and December 2019. Id. ¶¶ 16-20. As alleged in the Complaint, throughout this period, LEAF repeatedly made false representations to RSSB about the status of its patents and business. Id. ¶¶ 34-35. In response to RSSB’s repeated requests for information, LEAF later revealed that, contrary to its prior representations to RSSB, LEAF did not own the intellectual property, patents, and patent applications that applied to LEAF’s products; Niyikiza and LEAF had used RSSB’s investments to enrich Niyikiza personally; and LEAF had been paying its employees to work for other Holdings affiliates. Id.

Premised on these allegations, the Complaint alleges claims for fraud, negligent misrepresentation, and equitable fraud against LEAF and Niyikiza; a claim for unjust enrichment against Niyikiza and Holdings; and a derivative claim for breach of LEAF’s limited liability company agreement. Id. ¶¶ 41-74. The Complaint seeks, among other relief, compensatory damages, rescissory damages, and rescission of the Unit Purchase Agreement.

C.A. No. 2022-0987-BWD December 8, 2023 Page 4 of 15

B. The Counterclaims On January 5, 2023, Defendants filed the Counterclaims. The Counterclaims allege that since 2020, the finances of the government of Rwanda and RSSB have been under scrutiny by the International Monetary Fund (“IMF”). Countercls. ¶ 5. As alleged in the Counterclaims, IMF repeatedly set deadlines for RSSB to hire an independent advisory firm to analyze RSSB’s asset allocations, but RSSB delayed its compliance efforts and failed to meet those deadlines. Id. ¶¶ 6-13.

The Counterclaims further allege that in April 2022, RSSB finally engaged an advisory firm, at which time RSSB knew that it would soon face public backlash for its failed investments. Id. ¶¶ 12, 15. Namely, in 2009, RSSB “invested approximately $16 million in a start-up pharmaceutical company, for which RSSB did not receive the anticipated return on its investment, and for which RSSB has since been publicly criticized.” Id. ¶ 19. According to the Counterclaims, RSSB knew that once its investment in LEAF became public, RSSB would “endure substantial criticism and adverse political consequences”—“that is, RSSB knew that it would have to justify why, after an adverse experience with a prior pharmaceutical start-up investment, RSSB invested $40 million in LEAF, an early stage pharmaceutical start-up that was in the initial stages of developing proprietary drug products, rather than investing its pension and similar assets in a more conservative,

C.A. No. 2022-0987-BWD December 8, 2023 Page 5 of 15

predictable and less speculative manner.” Id. ¶ 22. To preempt criticism, “RSSB filed the Complaint so it could falsely represent on an ostensibly credible platform and as a matter of public record that RSSB had been defrauded by the Defendants into making the investment, and that, therefore, RSSB could not be blamed for its investment decisions.” Id. ¶ 23. Premised on these allegations, the Counterclaims allege a claim against RSSB for abuse of process. Id. ¶¶ 1-44.

Additionally, the Counterclaims allege that immediately prior to the filing of the Complaint, Defendants were negotiating a “prospective contractual relationship” with a “potential acquirer” valued “well in excess of $2 billion.” Id. ¶¶ 46-47. According to the Counterclaims, “[t]he potential acquirer had completed all due diligence, it confirmed that it wanted to finalize the transaction, it made a written proposal, and Defendants accepted the proposal,” but “RSSB intentionally interfered with and prevented the prospective contractual relationship from occurring by, inter alia, filing and maintaining the Complaint based on falsehoods, and then refusing to withdraw the Complaint without prejudice and refusing to place the lawsuit on hold, all without prejudice, pending efforts to finalize the transaction, all for unlawful purposes, knowing the effect such actions would have (and did have) on the prospective contractual relationship.” Id. ¶¶ 48-49. Premised on these allegations,

C.A. No. 2022-0987-BWD December 8, 2023 Page 6 of 15

the Counterclaims allege a claim against RSSB for tortious interference with prospective contractual relations. Id. ¶¶ 45-52.

The Counterclaims seek, among other relief, compensatory and punitive damages.1

C. The Motion to Dismiss On January 25, 2023, RSSB moved to dismiss the Counterclaims (the “Motion

Free access — add to your briefcase to read the full text and ask questions with AI

Rwanda Social Security Board v. L.E.A.F. Pharmaceuticals, LLC, (Del. Ct. App. 2023).

Rwanda Social Security Board v. L.E.A.F. Pharmaceuticals, LLC (Rwanda Social Security Board v. L.E.A.F. Pharmaceuticals, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re General Motors (Hughes) Shareholder Litigation
897 A.2d 162 (Supreme Court of Delaware, 2006)
Orman v. Cullman
794 A.2d 5 (Court of Chancery of Delaware, 2002)
Mariana v. Fisher
226 F. Supp. 2d 575 (M.D. Pennsylvania, 2002)
Organovo Holdings, Inc. v. Dimitrov
162 A.3d 102 (Court of Chancery of Delaware, 2017)